Annovis Bio (ANVS) News Today $5.01 +0.55 (+12.33%) (As of 12/24/2024 05:19 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Annovis Bio (NYSE: ANVS) Committed to Ensuring Highest Standards in Buntanetap TrialsDecember 23 at 4:30 PM | theglobeandmail.comBrokerages Set Annovis Bio, Inc. (NYSE:ANVS) Price Target at $32.17December 20, 2024 | americanbankingnews.comAnnovis Bio-Aktie erreicht 52-Wochen-Tief bei 4,52 US-DollarDecember 19, 2024 | de.investing.comShort Interest in Annovis Bio, Inc. (NYSE:ANVS) Declines By 5.8%Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) was the recipient of a significant decline in short interest during the month of November. As of November 30th, there was short interest totalling 1,310,000 shares, a decline of 5.8% from the November 15th total of 1,390,000 shares. Based on an average daily trading volume, of 254,500 shares, the days-to-cover ratio is presently 5.1 days.December 17, 2024 | marketbeat.comAnnovis Bio, Inc. (NYSE:ANVS) Receives Consensus Rating of "Buy" from AnalystsAnnovis Bio, Inc. (NYSE:ANVS - Get Free Report) has been given a consensus rating of "Buy" by the seven brokerages that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strongDecember 17, 2024 | marketbeat.comAnnovis Bio Advances Alzheimer’s and Parkinson’s Drug TrialsDecember 12, 2024 | markets.businessinsider.comAnnovis Bio Appoints William Fricker as Interim CFODecember 10, 2024 | markets.businessinsider.comAnnovis Bio ernennt Interims-CFODecember 9, 2024 | de.investing.comAnnovis Bio (NYSE: ANVS) CEO Shares Insight on Breakthrough Drug Showing Promise for Neurodegenerative DiseasesDecember 5, 2024 | theglobeandmail.comAnnovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today’s MarketplaceDecember 5, 2024 | finance.yahoo.comAnnovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's MarketplaceDecember 5, 2024 | globenewswire.com/C O R R E C T I O N -- Today's Marketplace/December 4, 2024 | prnewswire.comAnnovis Bio Announces Investor Webcast to Share Key UpdatesNovember 29, 2024 | msn.comAnnovis to Host Year-End Investor Webcast on December 11, 2024November 25, 2024 | globenewswire.comAnnovis Bio, Inc. (NYSE:ANVS) Receives Consensus Recommendation of "Buy" from AnalystsShares of Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) have earned a consensus recommendation of "Buy" from the seven research firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and onNovember 22, 2024 | marketbeat.comStrategic Buy Rating on Annovis Bio Amid Regulatory Alignment and Growth Potential in Alzheimer’s MarketNovember 15, 2024 | markets.businessinsider.comQ4 Earnings Estimate for Annovis Bio Issued By HC WainwrightAnnovis Bio, Inc. (NYSE:ANVS - Free Report) - HC Wainwright dropped their Q4 2024 earnings estimates for shares of Annovis Bio in a report released on Monday, November 11th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.38) for the quarter, doNovember 14, 2024 | marketbeat.comAnnovis Bio Advances Alzheimer’s Treatment with Phase 3 Trials and Financial UpdatesNovember 13, 2024 | msn.comAnnovis Bio (NYSE: ANVS) CEO to Showcase Buntanetap’s Dual Benefits at NIA WorkshopNovember 12, 2024 | theglobeandmail.comAnnovis sees cash runway for Phase 3 preparatory studies, entering AD studyNovember 12, 2024 | markets.businessinsider.comAnnovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)November 12, 2024 | markets.businessinsider.comBuy Rating for Annovis Bio Driven by Promising Regulatory Progress and Potential of BuntanetapNovember 12, 2024 | markets.businessinsider.comAnnovis Bio (NYSE: ANVS) Advances Alzheimer’s Phase 3 Trials with Strong FDA Support, Financial BackingNovember 11, 2024 | theglobeandmail.comAnnovis Bio Reports Third Quarter Financial Results and Provides Business UpdateNovember 11, 2024 | markets.businessinsider.comWill Annovis Bio (NYSE:ANVS) Spend Its Cash Wisely?November 11, 2024 | finance.yahoo.comAnnovis Bio (NYSE:ANVS) Earns "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $30.00 price target on shares of Annovis Bio in a research report on Monday.November 11, 2024 | marketbeat.comAnnovis Bio Welcomes New Senior Clinical Scientist to Lead Key StudiesNovember 9, 2024 | msn.comAnnovis Bio, Inc.: Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical ScientistNovember 7, 2024 | finanznachrichten.deAnnovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical ScientistNovember 7, 2024 | markets.businessinsider.comAnnovis Bio appoints Peterson as Senior Clinical ScientistNovember 7, 2024 | markets.businessinsider.comIBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis BioOctober 31, 2024 | globenewswire.comAnnovis Bio (NYSE: ANVS) Moving Closer to Providing Much-Needed Treatments to PatientsOctober 30, 2024 | theglobeandmail.comAnnovis Bio, Inc. (NYSE:ANVS) Given Consensus Rating of "Buy" by BrokeragesShares of Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) have earned a consensus rating of "Buy" from the seven research firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one hasOctober 28, 2024 | marketbeat.comMaxim Group Upgrades Annovis Bio (ANVS)October 26, 2024 | msn.comAnnovis Bio (NYSE: ANVS) Receives FDA Clearance to Initiate Pivotal Phase 3 Alzheimer’s StudiesOctober 25, 2024 | theglobeandmail.comAnnovis Bio upgraded to Buy at Maxim following buntanetap updateOctober 25, 2024 | markets.businessinsider.comAnnovis Bio (NYSE:ANVS) Upgraded at Maxim GroupMaxim Group raised shares of Annovis Bio from a "hold" rating to a "buy" rating and set a $25.00 price target on the stock in a report on Friday.October 25, 2024 | marketbeat.comAnnovis Bio to Present Key Alzheimer’s Research at CTAD ConferenceOctober 24, 2024 | msn.comAnnovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024October 23, 2024 | finance.yahoo.comAnnovis Bio Shows Promise on FDA Clearance for Alzheimer's DrugOctober 18, 2024 | finance.yahoo.comAnnovis Bio-Aktien behalten Kaufempfehlung von HC WainwrightOctober 16, 2024 | de.investing.comAnnovis Bio Advances Alzheimer’s Treatment with FDA Approval for Phase 3 TrialsOctober 16, 2024 | msn.comAnnovis Bio’s Promising Phase 3 Trials and Favorable Valuation Drive Buy RatingOctober 16, 2024 | markets.businessinsider.comAnnovis Bio (NYSE:ANVS) Rating Reiterated by HC WainwrightHC Wainwright restated a "buy" rating and issued a $30.00 price objective on shares of Annovis Bio in a report on Wednesday.October 16, 2024 | marketbeat.comFDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAsOctober 15, 2024 | finance.yahoo.comFDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAsOctober 15, 2024 | globenewswire.comAnnovis Bio Inc. (NYSE: ANVS) Seeking to Strengthen Intellectual Property Portfolio, Protecting Multifaceted Approach for Treatment of Neurodegenerative DiseasesOctober 4, 2024 | msn.comAnnovis Bio stock outlook supported by innovative neurodegenerative therapiesOctober 3, 2024 | uk.investing.comAnnovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative DiseasesOctober 3, 2024 | globenewswire.comAnnovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative CombinationsOctober 2, 2024 | globenewswire.com Get Annovis Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter. Email Address liberals FOOLED by Elon’s shocking surprise (Ad)Elon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the liberals broke”... But it turns out that was all just a smokescreen to hide the TRUTH… Click here to discover the real reason Elon Musk became buddy-buddy with Trump. ANVS Media Mentions By Week ANVS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANVS News Sentiment▼0.250.66▲Average Medical News Sentiment ANVS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANVS Articles This Week▼33▲ANVS Articles Average Week Get Annovis Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Aurora Cannabis News Today Zentalis Pharmaceuticals News Today DiaMedica Therapeutics News Today Molecular Partners News Today ProQR Therapeutics News Today LifeVantage News Today SOPHiA GENETICS News Today Inhibrx News Today Aclaris Therapeutics News Today Lexeo Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ANVS) was last updated on 12/26/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredElon Musk could help pay for your retirementElon Musk is the richest man in the world... And he's pouring trillions into a unique investment.Brownstone Research | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annovis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annovis Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
